
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles
Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector
South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment
NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...